Xiaonan Zhou

Cardiomyopathy comprises heterogeneous diseases characterized by structural or functional myocardial abnormalities and caused by conditions such as hypertension and coronary atherosclerotic heart disease. Current management relies mainly on pharmacotherapy and lifestyle interventions, but these approaches are limited by poor bioavailability and adverse effects. Nanoparticles (NPs) can deliver therapeutic drugs to cardiac muscle tissue through passive or active targeting, protecting the drugs they carry from premature degradation. They also show good biocompatibility and minimize damage to healthy tissues. This review summarizes the applications of NPs in cardiomyopathy and their active and passive targeting strategies, and provides a brief overview based on the mechanisms reported in individual published studies. It aims to provide therapeutic strategies for clinical management of cardiomyopathy and a theoretical foundation for future translational research.

INPLASY202650095 Regional Disparities and Driving Factors of Third-child Fertility Intention Among Reproductive-age Populations in Eastern China : A Systematic Review and Meta-Analysis Keywords: Ea…

INPLASY202630104 Third-Child Fertility Intention and Influencing Factors among Women of Childbearing Age：Systematic Review and Meta-analysis Keywords: Intention to have a third child, meta-analysis…

Low fertility has become a worldwide issue. Persistently low fertility, together with population contraction and ageing, will pose serious economic challenges and increase pressure on health systems, social security programs, and the labour force [1]. According to the United Nations World Population Prospects 2024, more than half of countries and regions worldwide have fertility below […]